Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | CD40 ligand |
Clinical data | |
AHFS/Drugs.com | Monograph |
License data |
|
Legal status | |
Legal status |
|
Identifiers | |
ChemSpider |
|
KEGG |
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.[1][2][3][4][5][6]
Demyelinating diseases of the central nervous system | |||||||||
---|---|---|---|---|---|---|---|---|---|
Signs and symptoms | |||||||||
Investigations and diagnosis | |||||||||
Approved treatment | |||||||||
Other treatments | |||||||||
Demyelinating diseases |
| ||||||||
Other |
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|